Investor Presentaiton
R&D investor presentation
42
We continue progressing on the strategic aspirations
Purpose and
sustainability
༢
Commercial
execution
0
Being respected for adding value to society
Progress towards zero environmental impact
Ensure distinct core capabilities and evolve culture
•
•
Patient flows impacted by COVID-19, but early signs
of recovery
Early RybelsusⓇ uptake further supports GLP-1 NBRX
and TRX market leadership in the US
While barriers in the obesity market still remain,
recent readouts are important milestones to achieve
the aspiration of more than doubling obesity sales¹
III
Financials
Innovation and
therapeutic focus
⚫|||||
•
•
•
•
•
Once-weekly insulin progressing to phase 3
Semaglutide showed encouraging profile in NASH
Strategic expansion into CVD with acquisition of
Corvidia
Semaglutide 2.4mg in obesity phase 3 results
Promising result of AM833 and Semaglutide in
obesity
Deliver solid sales and operating profit growth
•
Deliver 6-10% sales growth in IO
Transform 70% of sales in the USA²
Drive operational efficiencies across the value
chain to enable investments in future growth
assets
Deliver free cash flow to enable attractive capital
allocation to shareholders
1 Based on reported sales in 2019, 2 From 2015 to 2022. IO: International Operatons; CVD: Cardiovascular disease; NASH: Non-alcoholic steatohepatitis; CKD: Chronic kidney disease.View entire presentation